High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench.
Levy
Yishai
Y
D000818:Animals; D000924:Anticholesteremic Agents / Q000009:adverse effects*; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000378:metabolism; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008076:Cholesterol, HDL / Q000378:metabolism*; D008078:Cholesterol, LDL / Q000378:metabolism; D004359:Drug Therapy, Combination; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008264:Macrophages / Q000187:drug effects* / Q000378:metabolism; D011758:Pyrroles / Q000627:therapeutic use; D011804:Quinolines / Q000009:adverse effects*; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; C506642:CETP protein, human; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D011804:Quinolines; C483909:torcetrapib; D000069059:Atorvastatin